Entera Bio to Report First Quarter 2022 Financial Results on May 12
Entera Bio Ltd (NASDAQ: ENTX) will report its business and financial results for Q1 2022 on May 12, 2022, at 8:30 AM EDT. The company focuses on developing orally delivered large-molecule therapeutics to address significant unmet medical needs. Entera's advanced candidates include EB613 for osteoporosis and EB612 for hypoparathyroidism, which are currently in clinical development. The company also collaborates with biopharmaceutical firms, including Amgen Inc., licensing its proprietary drug delivery technology.
- Developing orally delivered large-molecule therapeutics, addressing unmet medical needs.
- Advanced candidates EB613 and EB612 in clinical development.
- Collaboration established with Amgen Inc. for technology licensing.
- None.
BOSTON and JERUSALEM, April 28, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report business and financial results for the three months ended March 31, 2022 on Thursday, May 12, 2022 at 8:30 AM EDT.
Thursday, May 12, 2022, 8:30 AM EDT
Domestic: 877-269-7756
International: 201-689-7817
Israel: 1809406247
Conference ID: 13728252
Webcast: Entera Bio Earnings Webcast
A replay of the webcast will be archived on Entera’s website for approximately 45 days following the call.
About Entera Bio
Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company’s proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company’s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in clinical development. The Company recently completed the phase 2 study for EB613. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.
Investors:
Nicole Jones
CG Capital
404-736-3838
entx@cg.capital
FAQ
When will Entera Bio report its Q1 2022 financial results?
What are the main products Entera Bio is developing?
Is Entera Bio collaborating with any pharmaceutical companies?
What is Entera Bio's focus in drug development?
